Delaet Ingrid, Chief Regulatory Officer, has demonstrated a clear selling bias in her insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 53 transactions, all involving Neurocrine Biosciences, Inc. (NBIX), Ingrid has sold shares totaling approximately $4.64 million, compared to purchases valued at $1.60 million. Her recent activity, spanning from December 31, 2024, to February 13, 2026, includes six sales, with notable transactions on February 13, 2026, totaling $1.33 million, $91,104.08, and $93,834.72. These sales follow earlier dispositions, including $93,007.67 on February 3, 2025, and $88,124.66 on February 13, 2025, reinforcing a consistent pattern of divestment.
Ingrid’s transactions are primarily categorized as sales (code "S") and exercises of derivative securities (code "M"), with no recent purchases recorded. Her most significant sale occurred on February 13, 2026, amounting to $1.33 million, marking the largest single transaction in her recent history. While some filings indicate acquisitions (code "A") and dispositions (code "F") with no monetary value, the overall trend underscores a focus on reducing her holdings in NBIX. This activity aligns with her broader trading history, which reflects a strategic shift toward liquidating her position in the company over time.
AI-assisted summary